Archive - January 2025
Researchers identify genetic 'fingerprint' to predict drug resistance in bacteria
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
Harnessing generative AI to treat undruggable diseases
FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Albion Rye Associates: Account Director – Corporate PR
Microbial therapy offers new hope for vitiligo patients
FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease
Skin cancer: New treatment option successfully tested